Thank you for taking part

This study explores how oncologists in the United States approach treatment decisions in advanced cancer, and what they would value in a new therapy.

Questions20

Choice tasks9

Takes about20 min

Audio guideYes

Please note. The product profile described in this study is a blinded, hypothetical profile created for research purposes. It is not an approved medicine and no treatment recommendation is being made.

How would you like question audio? Play only when I choose ListenRecommended — nothing starts automatically Read every question aloudAudio starts after you begin the survey No question audioYou can turn it on later

How would you like to answer? Tap my answersClassic mode — click or tap the options, use Next to move on Answer by voice 🎤Speak numbers, text or option names. For grids and other controls, say “control” and the numbered badge; for fields add the value. Say “next field”, “next” or “back”. Free: uses your browser’s own speech recognition, no account needed

Mechanism	Novel mechanism of action; details blinded for this study
Pivotal trial	Randomised, controlled, Phase III versus current standard of care
Headline efficacy	Significant improvement in progression-free survival; overall survival data immature
Safety	Treatment-related Grade 3+ adverse events in approximately 30% of patients
Administration	As described in the choice tasks
Companion diagnostic	Broad NGS panel

Thank you for taking part

You can answer by speaking

Blinded target product profile